Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
WELLESLEY HILLS, Mass., March 21, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Source Precision Medicine, Inc. d/b/a/ Source MDx ("Source MDx") announced that the foundational patents of Source MDx will be offered for sale on April 29, 2011.
Source MDx holds a broad-based, array of patents that cover technical aspects of RNA transcript measurement, concepts surrounding normal ranges in healthy human subjects ("normals") and statistical methods generating multi-gene models for the discrimination of normals versus disease. Key patents comprise the foundation of Source MDx's intellectual property portfolio. These include:
A. Systems and Methods for Characterizing a Biological Condition or Agent using Precision Gene Expression (#6,692,916 issued 02.17.04)
B. Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles (#6,940,439 issued 11.01.05)
C. Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles (#6,964,850 pending)
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton or 781-27-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm Finn, Warnke & Gayton LLP of Wellesley Hills, Massachusetts (www.finnwarnkegayton.com). He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as Assignee for the Benefit of Creditors and Liquidating Agent for corporations. He has been involved in a number of loan workouts and bankruptcy cases for thirty-six (36) years. His most recent